Tacrolimus suppresses tumour necrosis factor-alpha and protects against splanchnic artery occlusion shock
- PMID: 10385251
- PMCID: PMC1566016
- DOI: 10.1038/sj.bjp.0702528
Tacrolimus suppresses tumour necrosis factor-alpha and protects against splanchnic artery occlusion shock
Abstract
1. Tumour necrosis factor (TNF-alpha) is a pleiotropic cytokine which is deeply involved in the pathogenesis of splanchnic artery occlusion (SAO) shock. Tacrolimus, formerly known as FK506, is a macrolide antibiotic, that blocks the transcription of several proinflammatory cytokines including TNF-alpha. 2. Male anaesthetized rats were subjected to clamping of the splanchnic arteries for 45 min. This surgical procedure resulted in an irreversible state of shock (SAO shock). Sham operated animals were used as controls. SAO shocked rats had a decreased survival rate (0% at 4 h of reperfusion, while sham shocked rats survived more than 4 h), enhanced serum TNF-alpha concentrations (415+/-12 U ml(-1)), decreased mean arterial blood pressure (MAP), leukopenia and increased ileal leukocyte accumulation studied by means of myeloperoxidase activity (MPO=7.5+/-0.3 U g(-1) tissue). Moreover aortic rings from shocked rats showed a marked hyporeactivity to phenylephrine (PE, 1 nM - 10 microM), reduced responsiveness to acetylcholine (ACh, 10 nM - 10 microM) and increased staining for intercellular adhesion molecule-1 (ICAM-1). Furthermore increased mRNA for TNF-alpha was observed in peritoneal macrophages of SAO shocked rats. 3. Tacrolimus (100 microg kg(-1), 5 min after splanchnic arteries occlusion) increased survival rate (SAO + Tacrolimus = 100% at 4 h of reperfusion), reverted the marked hypotension, reduced serum TNF-alpha (15+/-3 U ml(-1)), ameliorated leukopenia, reduced ileal MPO (0.9+/-0.01 U g(-1) tissue), restored to control values the hyporeactivity to PE. improved the reduced responsiveness to ACh and blunted the enhanced immunostaining for ICAM-1 in the aorta. Finally tacrolimus suppressed cytokine mRNA levels in peritoneal macrophages. 4. The data suggest that tacrolimus may represent a new therapeutic approach in circulatory shock.
Figures





Similar articles
-
Adrenocorticotropin reverses vascular dysfunction and protects against splanchnic artery occlusion shock.Br J Pharmacol. 1999 Oct;128(3):816-22. doi: 10.1038/sj.bjp.0702848. Br J Pharmacol. 1999. PMID: 10516667 Free PMC article.
-
Effects of S-ethylisothiourea, a potent inhibitor of nitric oxide synthase, alone or in combination with a nitric oxide donor in splanchnic artery occlusion shock.Br J Pharmacol. 1996 Sep;119(1):23-8. doi: 10.1111/j.1476-5381.1996.tb15672.x. Br J Pharmacol. 1996. PMID: 8872352 Free PMC article.
-
Participation of tumour necrosis factor and nitric oxide in the mediation of vascular dysfunction in splanchnic artery occlusion shock.Br J Pharmacol. 1994 Dec;113(4):1153-8. doi: 10.1111/j.1476-5381.1994.tb17118.x. Br J Pharmacol. 1994. PMID: 7889268 Free PMC article.
-
Sulfatide reduces leucocyte accumulation and reverts vascular failure in splanchnic artery occlusion shock.Eur J Pharmacol. 1998 Nov 13;361(1):101-8. doi: 10.1016/s0014-2999(98)00705-5. Eur J Pharmacol. 1998. PMID: 9851547
-
Recombinant human erythropoietin inhibits iNOS activity and reverts vascular dysfunction in splanchnic artery occlusion shock.Br J Pharmacol. 1999 May;127(2):482-8. doi: 10.1038/sj.bjp.0702521. Br J Pharmacol. 1999. PMID: 10385249 Free PMC article.
Cited by
-
Hydrogen sulfide [corrected] increases survival during sepsis: protective effect of CHOP inhibition.J Immunol. 2014 Feb 15;192(4):1806-14. doi: 10.4049/jimmunol.1300835. Epub 2014 Jan 8. J Immunol. 2014. PMID: 24403532 Free PMC article.
-
Protective effects of a new stable, highly active SOD mimetic, M40401 in splanchnic artery occlusion and reperfusion.Br J Pharmacol. 2001 Jan;132(1):19-29. doi: 10.1038/sj.bjp.0703775. Br J Pharmacol. 2001. PMID: 11156557 Free PMC article.
References
-
- AKITA K., DUSTING G.J., HICKEY H. Suppression of nitric oxide production by cyclosporin A and FK506A in rat vascular smooth muscle cells. Clin. Exp. Pharmacol. Physiol. 1994;21:231–233. - PubMed
-
- ALTAVILLA D., BERLINGHIERI M.C., SEMINARA S., IANNELLO D., FOCA A., MASTROENI P. Different effects of bacterial lipopolysaccharide on superoxide anion production by macrophages from normal and tumor bearing rats. Immunopharmacology. 1989;17:99–105. - PubMed
-
- AOKI N., JOHNSON G., III, LEFER A.M. Beneficial effects of two forms of NO administration in feline splanchnic artery occlusion shock. Am. J. Physiol. 1990;321:G275–G281. - PubMed
-
- ARREAZA G., YOSHIKAWA N., MUKUTA T., RETKOVA E., BARSUK A., NISHIKAWA M., MUALLIM C., MILLER N., JAMIESON C., VOLPE R. Expression of intercellular adhesion molecule-1 on human thyroid cells from patients with autoimmune thyroid disease: study of thyroid xenografts in nude and severe combined immunodeficient mice and treatment with FK-506. J. Clin. Endocrinol. Metab. 1995;80:3724–3731. - PubMed
-
- BIERERBE, JIN Y.J., FRUMAN D.A., CALVO V, BURAKOFF S.J. FK506 and rapamycin: molecular probes of T-lymphocyte activation. Transplant. Proc. 1991;23:2850–2855. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous